Etentamig with Iberdomide

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Near Add Your Location

Sorting 13 by

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients
  • Show Principal Investigator
Rutgers Cancer Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, NJ
  • Accepting patients
Beverly Hills Cancer Center
Beverly Hills, CA
  • Accepting patients
Alvin J. Siteman Cancer Center
Washington University Medical Campus
St. Louis, MO
  • Accepting patients
Memorial Sloan Kettering Nassau
Uniondale, NY
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Bergen
Montvale, NJ
  • Accepting patients
  • Show Principal Investigator
Memorial Sloan Kettering Westchester
West Harrison, NY
  • Accepting patients
  • Show Principal Investigator
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
Memorial Sloan Kettering Commack
Commack, NY
  • Accepting patients
  • Show Principal Investigator

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.